Acumen pharmaceuticals showcases ptau217 trial screening progress in phase 2 altitude-ad trial and preclinical research methods at ad/pd 2025 and aan annual meeting

Biomarker results from phase 1 intercept-ad trial of sabirnetug in patients with early alzheimer's disease recently published in the journal of prevention of alzheimer's disease biomarker results from phase 1 intercept-ad trial of sabirnetug in patients with early alzheimer's disease recently published in the journal of prevention of alzheimer's disease
ABOS Ratings Summary
ABOS Quant Ranking